Savant Capital LLC Grows Position in AstraZeneca PLC $AZN

Savant Capital LLC raised its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 15.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,489 shares of the company’s stock after acquiring an additional 7,050 shares during the period. Savant Capital LLC’s holdings in AstraZeneca were worth $3,738,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of AZN. NewSquare Capital LLC grew its holdings in shares of AstraZeneca by 149.3% in the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after purchasing an additional 218 shares in the last quarter. Larson Financial Group LLC raised its stake in AstraZeneca by 297.9% during the first quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock valued at $28,000 after purchasing an additional 289 shares in the last quarter. Richardson Financial Services Inc. lifted its position in AstraZeneca by 59.8% during the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after purchasing an additional 149 shares during the last quarter. Costello Asset Management INC purchased a new position in shares of AstraZeneca in the 1st quarter worth $29,000. Finally, Maseco LLP purchased a new position in shares of AstraZeneca in the 2nd quarter worth $34,000. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Trading Up 1.0%

NASDAQ AZN opened at $84.58 on Monday. The stock has a market cap of $262.32 billion, a PE ratio of 31.80, a PEG ratio of 1.52 and a beta of 0.34. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $86.57. The company’s 50-day moving average price is $81.41 and its 200-day moving average price is $75.60. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. The company had revenue of $15.19 billion during the quarter, compared to analyst estimates of $14.75 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The firm’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter last year, the business posted $2.08 EPS. Equities research analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Jefferies Financial Group initiated coverage on AstraZeneca in a report on Monday, October 27th. They set a “buy” rating on the stock. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Thursday, October 16th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.